Sana Biotechnology, Mayo Clinic form strategic collaboration on type 1 diabetes cell therapy SC451
PUBT · 1d ago
Share
Listen to the news
- Sana Biotechnology entered strategic collaboration with Mayo Clinic to advance SC451, its investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes.
- Work will focus on validating and standardizing protocols for product handling, delivery, and post-treatment care to support consistent rollout across Mayo sites and other global centers.
- Partnership aims to accelerate SC451 toward a clinical trial Sana plans to start in 2026.
- Mayo Clinic will make an equity investment in Sana, with option for an additional investment under agreement terms.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief on April 13, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved